Big Pharma-Biotech Dealmaking: Less Prolific, More Expensive
Executive Summary
While each year seems to bring Big Pharma/Biotech deals of record-breaking valuations, on the whole, these deals have steadily declined since 1997, according to statistics presented in this month's Allliance Watch.